Daratumumab-induced in vivo immune modulation in relapsed and/refractory multiple myeloma patients treated with daratumumab-len-dex

被引：0

作者：

Giannotta, Claudia ^{[1
]}

Ziccheddu, Bachisio ^{[2
]}

D'Agostino, Mattia ^{[3
,4
]}

Bertuglia, Giuseppe ^{[5
]}

Saraci, Elona ^{[5
]}

Oliva, Stefania ^{[5
]}

Bolli, Niccolo' ^{[6
]}

Landgren, Ola ^{[7
]}

Bruno, Benedetto ^{[3
,4
]}

Boccadoro, Mario ^{[8
]}

Maura, Francesco ^{[7
]}

Massaia, Massimo ^{[1
]}

Larocca, Alessandra ^{[5
]}

机构：

[1] Univ Turin, Dept Mol Biotechnol & Hlth Sci, Mol Biotechnol Ctr Guido Tarone, Lab Blood Tumor Immunol, Turin, Italy

[2] Univ Miami, Coral Gables, FL 33124 USA

[3] Azienda Osped Univ Citta Salute & Sci Torino, Div Hematol, Turin, Italy

[4] Univ Turin, Div Hematol, Dept Mol Biotechnol & Hlth Sci, Turin, Italy

[5] Univ Turin, Azienda Osped Univ Citta Salute & Sci Torino, Div Ematol U, Myeloma Unit, Turin, Italy

[6] Univ Milan, Fdn IRCCS Ist Nazl Tumori, Div Hematol & Stem Cell Transplantat, Milan, Italy

[7] Univ Miami, Myeloma Div, Sylvester Comprehens Canc Ctr, Miami, FL USA

[8] Cattedra Ematol, Hematol Div, Dept Mol Biotechnol & Hlth Sci, Turin, Italy

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P-392

引用

页码：S256 / S257

页数：2

共 50 条

[31] Safety and Efficacy of Daratumumab with Lenalidomide and Dexamethasone in Relapsed or Relapsed, Refractory Multiple Myeloma
Plesner, Torben
Arkenau, Hendrik-Tobias
Lokhorst, Henk M.
Gimsing, Peter
Krejcik, Jakub
Lemech, Charlotte
Minnema, Monique C.
Lassen, Ulrik
Laubach, Jacob P.
Ahmadi, Tahamtan
Yeh, Howard
Guckert, Mary E.
Feng, Huaibao
Brun, Nikolai Constantin
Lisby, Steen
Basse, Linda
Palumbo, Antonio
Richardson, Paul G.
BLOOD, 2014, 124 (21)
[32] SAFETY AND EFFICACY OF DARATUMUMAB WITH LENALIDOMIDE AND DEXAMETHASONE IN RELAPSED OR RELAPSED, REFRACTORY MULTIPLE MYELOMA
Plesner, T.
Arkenau, H. T.
Lokhorst, H. M.
Gimsing, P.
Krejcik, J.
Lemech, C.
Minnema, M. C.
Lassen, U.
Ahmadi, T.
Yeh, H.
Guckert, M.
Brun, N. C.
Lisby, S.
Basse, L.
Palumbo, A.
Richardson, P. G.
HAEMATOLOGICA, 2014, 99 : 104 - 104
[33] Cost effectiveness of carfilzomib (CAR), ixazomib (IXA), elotuzumab (ELO), or daratumumab (DAR) with lenalidomide and dexamethasone (LEN plus DEX) vs LEN plus DEX in relapsed/refractory multiple myeloma (R/R MM).
Alsaid, Nimer
McBride, Ali
Agarwal, Amit Balkrishna
Mutairi, Abdulaali
Anwer, Faiz
Abraham, Ivo
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[34] Clinical Efficacy of Daratumumab, Pomalidomide and Dexamethasone in Relapsed, Refractory Myeloma Patients: Utility of Retreatment with Daratumumab Among Refractory Patients
Nooka, Ajay K.
Joseph, Nisha
Boise, Larry H.
Gleason, Charise
Kaufman, Jonathan L.
Lonial, Sagar
BLOOD, 2016, 128 (22)
[35] Daratumumab-lenalidomide and daratumumab-pomalidomide in relapsed lenalidomide-exposed or refractory multiple myeloma
Moustafa, Muhamad Alhaj
Parrondo, Ricardo
Abdulazeez, Mays F.
Roy, Vivek
Sher, Taimur
Alegria, Victoria R.
Warsame, Rahma M.
Fonseca, Rafael
Rasheed, Ahsan
Gonsalves, Wilson I.
Kourelis, Taxiarchis
Kapoor, Prashant
Buadi, Francis K.
Dingli, David
Hayman, Suzanne R.
Reeder, Craig B.
Chanan-Khan, Asher A.
Ailawadhi, Sikander
ANTI-CANCER DRUGS, 2024, 35 (01) : 63 - 69
[36] Genomic and immune determinants of resistance to daratumumab-based therapy in relapsed refractory multiple myeloma
Ziccheddu, Bachisio
Giannotta, Claudia
D'Agostino, Mattia
Bertuglia, Giuseppe
Saraci, Elona
Oliva, Stefania
Genuardi, Elisa
Papadimitriou, Marios
Diamond, Benjamin
Corradini, Paolo
Coffey, David
Landgren, Ola
Bolli, Niccolo
Bruno, Benedetto
Boccadoro, Mario
Massaia, Massimo
Maura, Francesco
Larocca, Alessandra
BLOOD CANCER JOURNAL, 2024, 14 (01):
[37] Practical considerations and role of Daratumumab retreatment for relapsed refractory Multiple Myeloma
Kim, E. Bridget
Harrington, Cynthia
Yee, Andrew
O'Donnell, Elizabeth
Branagan, Andrew
Burke, Jill
Raje, Noopur
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E263 - E263
[38] Weekly Carfilzomib Combined with Daratumumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
Xu, Jiadai
Liu, Peng
BLOOD, 2024, 144 : 7052 - 7053
[39] Efficacy of Once-Weekly Bortezomib with Daratumumab for Patients with Relapsed or Refractory Multiple Myeloma
Gut, Natalia
Yucebay, Filiz
Dempsey, Jessica
Li, Junan
Benson, Don M., Jr.
BLOOD, 2018, 132
[40] Daratumumab plus carfilzomib: An optimistic approach in relapsed/refractory multiple myeloma
Dubey, A. P.
Khatri, Sameer
Maggo, Sachin
Singh, Nilabh K.
Sharma, Durgesh
INDIAN JOURNAL OF MEDICAL AND PAEDIATRIC ONCOLOGY, 2020, 41 (06) : 846 - 849

← 1 2 3 4 5 →